Other Vaccines - Niger

Niger

Highlights

The revenue of the Other Vaccines market in Niger is projected to reach US$4.95m in 2024.
It is expected to show an annual growth rate (CAGR 2024-2029) of 11.61%, resulting in a market volume of US$8.57m by 2029.
In global comparison, United States is expected to generate the highest revenue in the market, amounting to US$24.73bn in 2024.
Niger has seen an increasing demand for other vaccines due to its efforts in expanding its immunization programs.

Key regions:

Market definitionIn-Scope/Out-of-scopeMarket structureReportsMethodology

The Other Vaccines market in Niger has been steadily developing over the past few years.

Customer preferences: Niger has a very young population, with over 50% of the population being under the age of 15. This means that there is a large demand for vaccinations, including Other Vaccines, which are used to prevent diseases such as meningitis and yellow fever. Additionally, the government of Niger has implemented a national vaccination program to ensure that all citizens have access to vaccines, which has further increased demand for Other Vaccines.

Trends in the market: One of the major trends in the Other Vaccines market in Niger is the increasing demand for meningitis vaccines. Niger is located in the "meningitis belt" of sub-Saharan Africa, which is an area that experiences frequent outbreaks of meningitis. As a result, there has been a significant increase in the number of meningitis vaccines being administered in Niger. Another trend in the Other Vaccines market is the growing awareness of the importance of vaccines among the population. This has led to an increase in demand for vaccines in general, including Other Vaccines.

Local special circumstances: Niger is a landlocked country in West Africa that faces a number of challenges, including a lack of infrastructure and a high poverty rate. This has made it difficult for the government to provide access to healthcare services, including vaccinations. However, the government has made significant efforts to address these challenges, including implementing a national vaccination program and partnering with international organizations to provide vaccines to the population.

Underlying macroeconomic factors: The economy of Niger is heavily dependent on agriculture, which accounts for over 40% of GDP. This has limited the government's ability to invest in healthcare infrastructure and other social services. Additionally, Niger has a high fertility rate, which has contributed to a rapidly growing population. This has put additional strain on healthcare services, including vaccination programs. However, despite these challenges, the government of Niger has made significant progress in improving access to vaccines, including Other Vaccines.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.